Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06484920 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
A Phase 2 study of B-cell Lymphoma and Refractory Non-Hodgkin Lymphoma, sponsored by Rita Assi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT06484920: Recruiting Phase 2 study of B-cell Lymphoma and Refractory Non-Hodgkin Lymphoma, sponsored by Rita Assi.
NCT06484920 is a Phase 2 study of B-cell Lymphoma and Refractory Non-Hodgkin Lymphoma that is actively recruiting participants, run by Rita Assi. The registered enrollment target is 24 participants, below the 90-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06484920, a Phase 2 study of B-cell Lymphoma and Refractory Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Rita Assi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.
Primary Outcome
Safety will be assess by the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG ATRA
Study Locations (2)
Indiana
- Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
- Sidney and Lois Eskenazi Hospital - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
What NCT06484920 shows while recruiting
NCT06484920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 90-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target (73% lower).
The record links to 5 conditions, with B-cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06484920 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT06484920 about?
NCT06484920 is a clinical study titled "A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL". This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.
What is the current status of trial NCT06484920?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-11-18. Estimated completion is 2029-09.
What conditions does trial NCT06484920 study?
This clinical trial studies the following conditions: B-cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin Lymphoma.
What interventions are being tested in trial NCT06484920?
The interventions under investigation include: Pembrolizumab (DRUG), ATRA (DRUG).
Who is sponsoring clinical trial NCT06484920?
This trial is sponsored by Rita Assi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06484920 being conducted?
This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06484920's enrollment target sits among peer trials
24 29th of 38 higher than 10 of 38 other B-cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other B-cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
RECRUITING · Phase 2
-
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI